TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02792218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab subcutaneous injection
Description: Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide-matching placebo capsules
Description: Placebo capsule, matching in appearance to teriflunomide, taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide capsule
Description: Teriflunomide 14 mg oral capsule taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo of ofatumumab subcutaneous injections
Description: Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study: NCT04509999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 Mg Oral Tablet
Description: Bicalutamide 150 mg by mouth daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as formulated by mouth daily
Study: NCT02273232

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care
Description: Standard Care for peripheral vascular disease patients including advises regarding exercises
Study: NCT01461460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 1200 mg
Description: 6 tablet of T-701 FA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: 1 tablet 400 mg Moxifloxacin
Study: NCT02273232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care for peripheral vascular disease patients including advises regarding exercises
Study: NCT00128193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: Licensed TB reagent, 100 microliters, 5 TU dose.
Study: NCT01461460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg plus Placebo
Description: 1 tablet of TR-701 FA with 5 tablet placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo tablets
Study: NCT03781479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Study: NCT00128193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: Licensed TB reagent, 100 microliters, 5 TU dose.
Study: NCT03781479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT03349697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phyllantus amarus

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phyllantus amarus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02800343

Intervention type: PROCEDURE
Intervention: routine administration of 0.9% sodium chloride
Description: 0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
Study: NCT02389517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT04325178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.
Description: Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.
Description: Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
Study: NCT02385682

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study: NCT02169479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo
Study: NCT00128193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: Licensed TB reagent, 100 microliters, 5 TU dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: Licensed TB reagent, 100 microliters, 5 TU dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (NaCl) serves as a diluent control in Stage A and B only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (NaCl) serves as a diluent control in Stage A and B only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (NaCl) serves as a diluent control in Stage A and B only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (NaCl) serves as a diluent control in Stage A and B only.
Study: NCT01981850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: IV infusion
Study: NCT00597519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Cyclophosphamide
Description: Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
Study: NCT02380313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
Study: NCT00410124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01649635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Granulocyte colony-stimulating factor)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT00578656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: Extensively heated milk
Study: NCT02955524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%
Description: One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride ophthalmic gel 3.5%
Description: 1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
Study: NCT02215278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 x 55 g/ bean per arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 x 55 g/ bean per arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 x 55 g/ bean per arm
Study: NCT01767259

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: Valsartan alone

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide alone
Study: NCT01026233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg IV every 21 days
Study: NCT01847651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vastus Muscle Biopsy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vastus Muscle Biopsy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOLA or placebo
Description: Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOLA or placebo
Description: Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive assessment (PHES)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive assessment (PHES)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessement (Cogstate)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study: NCT02380313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
Study: NCT02169479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Immediate-release levodopa/carbidopa 100/25 mg
Study: NCT01682642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
Study: NCT02614963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Butyricum
Description: Irritable bowel syndrome patients treated with Clostridium Butyricum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Irritable bowel syndrome patients treated with placebo
Study: NCT00346164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT02593487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg/d group
Description: rosuvastatin 10mg tablet,q.d. for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg/d group
Description: rosuvastatin 20mg tablet,q.d. for 12 weeks.
Study: NCT04471038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
Study: NCT02414373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2mg/ml
Description: local anesthetics, which will epidurally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetics, which will epidurally administered

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)
Study: NCT01402154

Intervention type: BIOLOGICAL
Intervention: EPISPOT detection of the number of circulating cells
Description: EPISPOT detection of the number of circulating, functional, prostate cells per unit blood

Intervention type: BIOLOGICAL
Intervention: CellSearch detection of the number of circulating, functional, prostate cells
Description: CellSearch detection of the number of circulating, functional, prostate cells per unit blood
Study: NCT02345291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRD135S.E1
Description: A small chemical entity for treatment of neuropathic pain NRD135S.E1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRD135S.E1
Description: A small chemical entity for treatment of neuropathic pain NRD135S.E1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRD135S.E1
Description: A small chemical entity for treatment of neuropathic pain NRD135S.E1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match NRD135S.E1
Description: Placebo capsule to match NRD135S.E1 capsules